Immune reconstitution to Aspergillus
针对曲霉菌的免疫重建
基本信息
- 批准号:7187401
- 负责人:
- 金额:$ 34.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-03-01 至 2011-02-28
- 项目状态:已结题
- 来源:
- 关键词:AddressAllelesAllergicAllergic Bronchopulmonary AspergillosisAllogenicAnimal ModelAntifungal AgentsAntigen-Presenting CellsAntigensAspergillosisAspergillusAspergillus fumigatusAutoantigensAutologousB-LymphocytesBiologicalBlast CellBloodCD4 Positive T LymphocytesCell CountCell ProliferationCell secretionCellsCellular ImmunityCessation of lifeChromosomes, Human, Pair 6ClassComplementary DNAComplexCox Proportional Hazards ModelsDNA SequenceDataDevelopmentEngraftmentEnrollmentEnvironmentEpidemiologyEpitopesExhibitsFrequenciesGenesGeneticGenetic PolymorphismGenetic VariationGenomicsGoalsHaplotypesHematopoietic Stem Cell TransplantationHematopoietic stem cellsHistocompatibility Antigens Class IIHumanHyphaeImmuneImmune responseImmunityImmunocompromised HostIncidenceIndividualInfectionInterferon Type IIInterleukin-4InvasiveKineticsKnowledgeLibrariesLongitudinal StudiesLungMHC Class II GenesMapsMeasuresMethodsMoldsMonitorMycosesNatural Killer CellsNeutropeniaNumbersOpen Reading FramesOutcomeOutcome MeasurePatientsPatternPerformancePeripheral Blood Mononuclear CellPhenotypePhysiologic pulsePolymerase Chain ReactionPopulationPredispositionPreparationPromoter RegionsProphylactic treatmentProteinsPulse takingRangeRateRecoveryResearch PersonnelRetrospective StudiesRiskRoleSample SizeSamplingScreening procedureStagingT-LymphocyteTestingTherapeuticTimeTransplant RecipientsTransplantationTumor Necrosis Factor-alphaVaccinesWeekattributable mortalitybasecell preparationcytokinedaydesignfungushealthy volunteerhuman TNF proteinimmune functionindexingmortalityneutrophilpreventprogramsreconstitutionresponsetrend
项目摘要
DESCRIPTION (provided by applicant): The annual incidence of invasive aspergillosis (IA) ranges from 10 to15% in allogeneic hematopoietic stem cell (HCT) recipients, with mortality approximating 80%; as such, this infection has become a prominent cause of infection-related death after HCT. Infection now occurs primarily late in the course of allogeneic HCT, after neutrophil engraftment. Epidemiology is consistent with the recent recognition that effective immunity in animal models requires robust CD4+ T helper type-1 (Th1) responses. However, no large studies have been performed to evaluate Aspergillus-specific immune reconstitution. We have developed the methods to measure cellular responses to Aspergillus antigens, and demonstrated reproducibly variable responses in healthy volunteers. We propose a longitudinal immune-reconstitution study to evaluate the hypothesis that CD4+ T cell reconstitution is important to protect from IA late after allogeneic HCT, with multiple factors, including donor transferred immunity, potentially impacting immune reconstitution. Specific aims will be to: 1. Determine if reconstituted cellular immunity predicts risks for, and outcomes of IA. Patients will be enrolled in a longitudinal study to evaluate whether reconstituted cell numbers (DC1, DC2, T cell subtypes, NK cells and B cells) and functional responses to A. fumigatus hyphal antigen predict risks for, and outcomes of IA. In Aim 2, studies will determine the significance of variable frequencies of reactive CD4+ T cells and cytokine patterns in healthy donors. Donor responses will be evaluated to test the hypothesis that low frequencies of IFN-gamma producing CD4+ T cells in healthy people are associated with MHC alleles, potentially including specific Class II haplotypes and/or polymorphism(s) in the Class III region (TNF-alpha gene). The impact of donor responses on recipient reconstitution will be evaluated. Studies in Aim 3 will identify Aspergillus fumigatus antigens presented to healthy human CD4+ T cells. Aspergillus-specific CD4+ T cell clones will be generated from healthy subjects by sequential stimulation with hyphal antigens. Classical HLA-restricted CD4+ clones will be used to screen pooled libraries of A. fumigatus cDNA, with sequential screens identifying individual T-cell antigens. This study will be performed with the goal of defining the mechanisms of post-transplant immune protection against Aspergillus species. This information will be valuable for development of strategies to prevent and treat fungal infections in immunocompromised people.
描述(申请人提供):在异基因造血干细胞(HCT)受者中,侵袭性曲霉病(IA)的年发病率从10%到15%不等,死亡率约为80%;因此,这种感染已成为HCT后感染相关死亡的主要原因。感染现在主要发生在同种异体红细胞移植过程的晚期,即中性粒细胞植入之后。流行病学与最近的认识是一致的,即动物模型的有效免疫需要强大的CD4+T辅助细胞1型(Th1)反应。然而,还没有进行大型研究来评估曲霉菌特异性的免疫重建。我们已经开发了测量细胞对曲霉菌抗原反应的方法,并在健康志愿者中展示了可重复性的可变反应。我们提出了一项纵向免疫重建研究,以评估CD4+T细胞重建对异基因HCT后晚期IA的保护作用这一假说,包括供者转移免疫在内的多种因素潜在地影响免疫重建。具体目标是:1.确定重组细胞免疫是否预测IA的风险和结果。患者将参加一项纵向研究,以评估重组细胞数量(DC1、DC2、T细胞亚型、NK细胞和B细胞)和对烟曲霉菌丝抗原的功能反应是否预测IA的风险和结果。在目标2中,研究将确定反应性CD4+T细胞的不同频率和细胞因子模式在健康捐赠者中的意义。将对捐献者的反应进行评估,以检验以下假设:健康人产生干扰素-伽马的CD+T细胞的低频率与MHC等位基因相关,可能包括特定的II类单倍型和/或III类区域(肿瘤坏死因子-α基因)的多态性(S)。将评估捐赠者反应对受者重建的影响。AIM 3中的研究将鉴定呈递给健康人类CD4+T细胞的烟曲霉菌抗原。曲霉菌特异性的CD4+T细胞克隆将通过菌丝抗原的顺序刺激从健康受试者中产生。经典的人类白细胞抗原限制性CD4+克隆将被用来筛选烟曲霉菌cDNA池文库,并通过顺序筛选识别单个T细胞抗原。这项研究的目的是明确移植后对曲霉菌的免疫保护机制。这些信息将对制定预防和治疗免疫受损人群真菌感染的策略很有价值。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kieren A. Marr其他文献
Signification clinique de la rsistance croise aux antifongiques azols chez Candida glabrata
光滑念珠菌抗性诊所的意义
- DOI:
- 发表时间:
2007 - 期刊:
- 影响因子:0
- 作者:
Anil A. Panackal;Jennifer L. Gribskov;Janet F. Staab;Katharine A. Kirby;M. G. Rinaldi;Kieren A. Marr - 通讯作者:
Kieren A. Marr
RG Finch, D Greenwood, SR Norrby, RJ Whitley, eds. Antibiotics and Chemotherapy: Anti-infective Agents and Their Use in Therapy (8th edition).
- DOI:
10.1023/b:myco.0000030766.97284.bc - 发表时间:
2004-05-01 - 期刊:
- 影响因子:2.900
- 作者:
Kieren A. Marr - 通讯作者:
Kieren A. Marr
Tratamiento de la Aspergilosis: Guías para la práctica clínica de la Sociedad de Enfermedades Infecciosas de los Estados Unidos de América (IDSA)
曲霉病治疗:美国联合感染协会 (IDSA) 临床实践指南
- DOI:
10.1086/590225 - 发表时间:
2008 - 期刊:
- 影响因子:11.8
- 作者:
Thomas J. Walsh;E. Anaissie;David W. Denning;Raoul Herbrecht;Dimitrios P. Kontoyiannis;Kieren A. Marr;Vicki A. Morrison;Brahm H Segal;William J. Steinbach;David A. Stevens;Jo;John R. Wingard;Thomas F. Patterson - 通讯作者:
Thomas F. Patterson
Invasive fungal infections after respiratory viral infections in lung transplant recipients are associated with lung allograft failure and chronic lung allograft dysfunction within 1 year
- DOI:
10.1016/j.healun.2023.02.005 - 发表时间:
2023-07-01 - 期刊:
- 影响因子:
- 作者:
Nitipong Permpalung;Tao Liang;Shilpa Gopinath;Katrina Bazemore;Joby Mathew;Darin Ostrander;Christine M. Durand;Shmuel Shoham;Sean X. Zhang;Kieren A. Marr;Robin K. Avery;Pali D. Shah - 通讯作者:
Pali D. Shah
Kieren A. Marr的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kieren A. Marr', 18)}}的其他基金
Patient Oriented Research in Transplant and Oncology ID
移植和肿瘤学 ID 领域以患者为导向的研究
- 批准号:
8461505 - 财政年份:2010
- 资助金额:
$ 34.65万 - 项目类别:
Patient Oriented Research in Transplant and Oncology ID
移植和肿瘤学 ID 领域以患者为导向的研究
- 批准号:
7988983 - 财政年份:2010
- 资助金额:
$ 34.65万 - 项目类别:
Patient Oriented Research in Transplant and Oncology ID
移植和肿瘤学 ID 领域以患者为导向的研究
- 批准号:
8074917 - 财政年份:2010
- 资助金额:
$ 34.65万 - 项目类别:
Patient Oriented Research in Transplant and Oncology ID
移植和肿瘤学 ID 领域以患者为导向的研究
- 批准号:
8652943 - 财政年份:2010
- 资助金额:
$ 34.65万 - 项目类别:
Patient Oriented Research in Transplant and Oncology ID
移植和肿瘤学 ID 领域以患者为导向的研究
- 批准号:
8259507 - 财政年份:2010
- 资助金额:
$ 34.65万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 34.65万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 34.65万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 34.65万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 34.65万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 34.65万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别: